Pirfenidone use in fibrotic diseases: What do we know so far?
Immunity, Inflammation and Disease · 2024-07 · 12 (7)
DOI: 10.1002/iid3.1335 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 05.07.2024. Verfasst von Aldo Torre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Unit, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico. Hauptthemen laut MEDLINE: Pyridones, Fibrosis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pirfenidone has demonstrated significant anti‐inflammatory and antifibrotic effects in both animal models and some clinical trials. Its potential for antifibrotic activity positions it as a promising candidate for the treatment of various fibrotic diseases. Pirfenidone exerts several pleiotropic and anti‐inflammatory effects through different molecular pathways, attenuating multiple inflammatory processes, including the secretion of pro‐inflammatory cytokines, apoptosis, and fibroblast activation.
Objective
To present the current evidence of pirfenidone's effects on several fibrotic diseases, with a focus on its potential as a therapeutic option for managing chronic fibrotic conditions.
Findings
Pirfenidone has been extensively studied for idiopathic pulmonary fibrosis, showing a favorable impact and forming part of the current treatment regimen for this disease. Additionally, pirfenidone appears to have beneficial effects on similar fibrotic diseases such as interstitial lung disease, myocardial fibrosis, glomerulopathies, aberrant skin scarring, chronic liver disease, and other fibrotic disorders.
Conclusion
Given the increasing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for these patients. However, further clinical trials are necessary to confirm its therapeutic efficacy in various fibrotic diseases. This review aims to highlight the current evidence of pirfenidone's effects in multiple fibrotic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Unit, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico.
- Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
- Department of Internal Medicine, Hospital General "Dr. Manuel Gea González", Mexico City, Mexico.
- Department of Hepatology, Hospital General "Dr. Manuel Gea González", Mexico City, Mexico.
ORCID-Profile: Aldo Torre, Froylan David Martínez-Sánchez, Sofía Mercedes Narvaez-Chávez, Mariana Ariel Herrera-Islas, Carlos Alberto Aguilar-Salinas, Jacqueline Córdova-Gallardo
Zitieren
APA
Torre, A., Martínez-Sánchez, F. D., Narvaez-Chávez, S. M., Herrera-Islas, M. A., Aguilar-Salinas, C. A., & Córdova-Gallardo, J. (2024). Pirfenidone use in fibrotic diseases: What do we know so far?. Immunity, Inflammation and Disease, 12(7). https://doi.org/10.1002/iid3.1335
Vancouver
Torre A, Martínez-Sánchez FD, Narvaez-Chávez SM, Herrera-Islas MA, Aguilar-Salinas CA, Córdova-Gallardo J. Pirfenidone use in fibrotic diseases: What do we know so far?. Immunity, Inflammation and Disease. 2024;12(7). doi:10.1002/iid3.1335
BibTeX
@article{Torre2024,
author = {Torre, Aldo and Martínez-Sánchez, Froylan David and Narvaez-Chávez, Sofía Mercedes and Herrera-Islas, Mariana Ariel and Aguilar-Salinas, Carlos Alberto and Córdova-Gallardo, Jacqueline},
title = {Pirfenidone use in fibrotic diseases: What do we know so far?},
journal = {Immunity, Inflammation and Disease},
year = {2024},
volume = {12},
number = {7},
doi = {10.1002/iid3.1335}
}
EUVIMED